Population-based study shows decreased costs of advanced therapies in inflammatory bowel disease, suggesting financial benefits of biosimilars.
This population-based study found increased advanced therapies use partially because of the higher IBD prevalence observed during the study period, but with decreasing costs, mainly attributable to the significant use of anti-tumor necrosis factor αlpha biosimilars.
No takes yet. Share an insight, caveat, or question.
Tursi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: